Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 million for its services.
Royalty Pharma plc (RPRX), Tuesday announced a $2 billion funding deal with Revolution Medicines, comprising of a synthetic royalty of upto $1.25 billion on annual worldwide net sales of daraxonrasib, and a senior secured loan of up to $750 million.
Jefferies analyst Kelly Shi in a Sunday note to investors said that both data drops for Revolution Medicines’ experimental RAS inhibitors are positive and could be “synergistic” in the first-line setting for pancreatic ductal adenocarcinoma.
In a presentation to investors Monday, Revolution Medicines said its RAS(ON) multi-selective inhibitor RMC-6236 will advance to Phase III testing in pancreatic cancer following encouraging results from a Phase I study. The biotech shared updated results showing tumour shrinkage of up to 27% in patients with pancreatic ductal adenocarcinoma (PDAC).
EQRx, a biotechnology company that sought to disrupt U.S. drug pricing practices, is being sold to cancer drugmaker Revolution Medicines in an all-stock deal, the companies announced Tuesday.
Back in 2018, Revolution Medicines launched its SHP2 inhibitor with a splash thanks to a $550 million licensing deal with Sanofi. But, after four years, Sanofi is docking the deal.
Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?
The RAS family of proteins are one of the hottest targets in cancer research despite being one of the hardest for drug hunters to hit. Revolution Medicines has raised $238 million in an IPO to finance development of therapies that it says can drug these molecules in a novel way.
Revolution Medicines, a Phase 1/2 biotech developing targeted cancer therapies using the RAS pathway, announced terms for its IPO on Monday.
The Redwood City, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Revolution Medicines would command a fully diluted market value of $850 million.